针对表皮生长因子受体突变肿瘤的非小细胞肺癌患者的新治疗方案。

Q1 Medicine

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Pub Date : 2024-04-01 DOI:10.1200/EDBK_432516

Stephanie P L Saw, Xiuning Le, Lizza E L Hendriks, Jordi Remon

{"title":"针对表皮生长因子受体突变肿瘤的非小细胞肺癌患者的新治疗方案。","authors":"Stephanie P L Saw, Xiuning Le, Lizza E L Hendriks, Jordi Remon","doi":"10.1200/EDBK_432516","DOIUrl":null,"url":null,"abstract":"Druggable oncogene-driven non-small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"44 3","pages":"e432516"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.\",\"authors\":\"Stephanie P L Saw, Xiuning Le, Lizza E L Hendriks, Jordi Remon\",\"doi\":\"10.1200/EDBK_432516\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Druggable oncogene-driven non-small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.\",\"PeriodicalId\":37969,\"journal\":{\"name\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"volume\":\"44 3\",\"pages\":\"e432516\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1200/EDBK_432516\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1200/EDBK_432516","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

可药用的癌基因驱动的非小细胞肺癌带来了创新的全身治疗方案，改善了患者的预后。这种益处不仅体现在转移性治疗中，也体现在手术后的治疗中，例如在携带常见致敏表皮生长因子受体（EGFR）突变或ALK重排的肺癌中。为了提高这些患者的治疗效果，我们需要了解获得性耐药的机制，并评估具有新作用机制的新药在治疗中的作用。在本章中，我们将回顾各阶段表皮生长因子受体突变肿瘤的治疗策略、获得性策略的机制以及该亚群的新型疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

New Treatment Options for Patients With Oncogene-Addicted Non-Small Cell Lung Cancer Focusing on EGFR-Mutant Tumors.

Druggable oncogene-driven non-small cell lung cancer has led to innovative systemic treatment options, improving patients' outcome. This benefit is not only achieved in the metastatic setting but also in the postsurgical setting, such as in lung cancers harboring a common sensitizing EGFR mutation or ALK-rearrangement. To enhance the outcome of these patients, we need to understand the mechanisms of acquired resistance and evaluate the role of new drugs with novel mechanisms of action in the treatment landscape. In this chapter, we review treatment strategies of EGFR-mutant tumors in all stages, the mechanisms of acquired strategies, and novel therapies in this subset.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting Medicine-Medicine (all)

自引率

0.00%

发文量

期刊介绍： The Ed Book is a National Library of Medicine–indexed collection of articles written by ASCO Annual Meeting faculty and invited leaders in oncology. Ed Book was launched in 1985 to highlight standards of care and inspire future therapeutic possibilities in oncology. Published annually, each volume highlights the most compelling research and developments across the multidisciplinary fields of oncology and serves as an enduring scholarly resource for all members of the cancer care team long after the Meeting concludes. These articles address issues in the following areas, among others: Immuno-oncology, Surgical, radiation, and medical oncology, Clinical informatics and quality of care, Global health, Survivorship.